Company: PDEX
Filing Date: 2025-05-01
Form Type: 10-Q
Source: 0001079973-25-000729
Chunk: 5

Company: PRO DEX INC
Filing Date: 2025-05-01
Form: 10-Q
Item: Item 8
Chunk 5
---
 – long-term	 
     —  
     1,563  
     —  
     1,563 
  
      Total 
    $45  
    $5,780  
    $—  
    $5,825 

Investments
in marketable equity securities at March 31, 2025 and June 30, 2024 had an aggregate cost basis of $2,651,000
and $3,964,000, respectively. The long-term investments include equity investments of thinly traded securities that we classified
as long term in nature because if we decide to sell these securities, we may not be able to sell our position within one year. During
the quarter ended March 31, 2025, we sold one of our marketable equity securities previously reported in long term investments for $1.9
million in cash and recorded a realized gain in the amount of $595,000. At March 31, 2025, the investments included net unrealized gains
of $2.9 million (gross unrealized gains of $3.4 million offset by gross unrealized losses of $493,000). At June 30, 2024, the investments
included net unrealized gains of $1.8 million (gross unrealized gains of $2.1 million offset by gross unrealized gains of $261,000).

Of
the total marketable equity securities at March 31, 2025 and June 30, 2024, $797,000 and $987,000, respectively, represent an investment
in the common stock of Air T, Inc. Two of our Board members are also board members of Air T, Inc. and both either individually or through
affiliates own an equity interest in Air T, Inc. Our Chairman, one of the two Board members aforementioned, also serves as the Chief Executive
Officer and Chairman of Air T, Inc. Another of our Board members is employed by Air T, Inc. as its Chief of Staff. The shares were purchased
through 10b5-1 Plans, that, in accordance with our internal policies regarding the approval of related-party transactions, were approved
by our then three Board members that are not affiliated with Air T, Inc.

On October
6, 2023, in conjunction with the execution of a supply agreement with Monogram Technologies, Inc., formerly Monogram Orthopaedics Inc.
(“Monogram”), we exercised